Nurofen maker slapped with $1.7 million in penalties for misleading claims


The makers of Nurofen have been fined $1.7 million over the misleading claim that some of its products offered targeted pain relief.

The ABC and others report that the Federal Court found the claims of “pain specific” products misleading. These all contained the same active ingredient – 342 mg of ibuprofen lysine – though were priced at nearly twice standard Nurofen.

“…[The] ACCC was particularly concerned that consumers had been misled into purchasing Nurofen Specific Pain  Products, and paying more for those products, in the belief that each product was specifically designed for and effective in treating a particular type of pain, when this was not the case,” ACCC Chairman Rod Sims said in a statement.

The Australian Competition and Consumer Commission took the pharmaceutical companyto court in March last year.

Reckitt’s lawyers argued that no “rational” consumer would believe the pain-specific products would offer more effective relief.

Leave a Reply